188 related articles for article (PubMed ID: 15037670)
1. Practical considerations in the use of apomorphine injectable.
Bowron A
Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
[TBL] [Abstract][Full Text] [Related]
2. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
Koller W; Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
[TBL] [Abstract][Full Text] [Related]
3. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
5. Rapid treatment of "wearing off" in Parkinson's disease.
Swope DM
Neurology; 2004 Mar; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine: North American clinical experience.
Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
[TBL] [Abstract][Full Text] [Related]
7. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Factor SA
Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
[TBL] [Abstract][Full Text] [Related]
8. [Apomorphine in the treatment of Parkinson's Disease].
Dressler D
Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
[TBL] [Abstract][Full Text] [Related]
9. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Clin Neuropharmacol; 1996 Jun; 19(3):193-201. PubMed ID: 8726538
[TBL] [Abstract][Full Text] [Related]
10. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
11. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
12. Use of apomorphine in clinical practice.
MacMahon DG
Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
[No Abstract] [Full Text] [Related]
13. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
14. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
Hauser RA; Isaacson S; Clinch T;
Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
[TBL] [Abstract][Full Text] [Related]
15. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
Giménez de Béjar V; Carballo-Cordero M
Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
[TBL] [Abstract][Full Text] [Related]
17. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
[TBL] [Abstract][Full Text] [Related]
18. [Apomorphine in treatment of Parkinson's disease with fluctuations].
Zaleska B; Domzał T
Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
[TBL] [Abstract][Full Text] [Related]
20. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Stefani A; Stanzione P; Bassi A; Mazzone P; Vangelista T; Bernardi G
J Neural Transm (Vienna); 1997; 104(8-9):895-904. PubMed ID: 9451721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
